Abstract | Patients with bilateral multifocal renal cell carcinoma are at increased risk of developing locally recurrent or de novo tumors after nephron-sparing procedures. When dealing with recurrent renal masses the options are limited to observation, total nephrectomy, ablation, or repeat surgical intervention. The main reason for recurrence after nephron-sparing surgery is likely to be the presence of multifocal disease, which is identified in 4.3-25.0% of radical nephrectomy specimen. Bilateral renal involvement is seen in almost 90% of cases of multifocal renal carcinoma, and conversely the majority of patients with bilateral disease will have multifocal tumors. Many patients who are treated for multifocal disease, therefore, require subsequent surgical interventions. The outcome data for repeat renal interventions demonstrate reasonable functional and oncologic outcomes despite higher rates of perioperative complications. Our own results support the use of reoperative renal surgery rather than total nephrectomy and renal replacement therapy.
Introduction
renal cell carcinoma (rCC) is the third most common genitourinary malignancy and a major health care concern worldwide. During 2009, kidney cancer will have been diagnosed in more than 57,000 patients and will have claimed the lives of almost 13,000 individuals in the usa. 1 the national incidence of rCC seems to be steadily rising by 3% per year.
2,3 the increased use of cross-sectional imaging and the consequent rise in the detection of renal masses can only partially explain the rising incidence of rCC. as many as one-third of all patients with rCC will present with metastatic disease and as many as half of patients who receive surgery for localized disease will fail either locally or, more commonly, distantly. [4] [5] [6] [7] identifying patients at high risk of local and distant failure has been one of the main focuses of clinical and basic research to date.
traditionally, patients with bilateral multifocal renal tumors are considered to have high-risk disease, mostly as a result of their propensity for locally recurrent tumors. indeed, the long-term follow-up of patients with von Hippel-lindau disease, which is characterized by the development of tumors in multiple organs including bilateral multifocal clear cell rCC, has demon strated that the vast majority of these patients will develop locally recurrent tumors within 10 years. 8 similarly, Blute and colleagues 9 observed a significantly higher rate of local recurrence in patients with bilateral nonhereditary renal masses compared with those who were treated for uni lateral rCC. not surprisingly, many patients who present with bilateral, multifocal bilateral, or multifocal ipsilateral renal tumors ultimately end up losing at least one of their renal units after undergoing radical nephrectomy. [10] [11] [12] while studies of patients with bilateral multi focal disease have enabled identification of a number of kidney cancer genes, the genetic basis of bilateral, multifocal kidney cancer in most patients remains to be determined. [13] [14] [15] although many investigators have reported excellent oncologic outcomes of patients with multi focal rCC treated by radical nephrectomy, the optimum manage ment approach for these patients remains unknown. [16] [17] [18] [19] [20] [21] [22] the main unanswered issues center around three questions. First, are patients with bilateral multifocal renal masses at high risk for distant failure and development of metastatic disease? second, does the presence of bilateral multifocal renal masses warrant bilateral nephrectomy or maximal renal preser vation? third, if renal preservation is chosen, is repeat renal surgery for local failure better than total nephrectomy? this review will address the long-term management of the challenging population of patients with bilateral multifocal renal masses. in order to answer the above questions we will consider a number of factors, including the frequency of bilaterality and multifocality of renal masses; the definition of local recurrence; the importance of maximal renal preservation; the outcomes of renal replacement therapy; and the outcomes of surgical management of recurrent rCC. 9,10 a recent multi-institutional study of synchronous bilateral rCC reported multifocality in 54% of patients. 11 Conversely, in one autopsy study the prevalence of bilaterality was almost 90% if multifocal rCC was present.
26 most important, however, is the recognition of the close association between bilateral renal masses and multifocality. multifocality in rCC has been studied extensively with regard to incidence, risk factors, and outcomes of patients who undergo surgical treatment. while multi focality seems to be present at greater frequency in patients with bilateral renal masses than in those without bilateral involvement (and more commonly in patients with synchronous than with metachronous masses), 10, 11, 27 its prevalence in the general population undergoing nephrectomy is not negligible. a review of studies from the past two decades that have evaluated multifocality in rCC reveals considerable variation among institutions in the frequency of multifocality identified in radical nephrectomy specimens. [17] [18] [19] 22, 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] multifocality has been observed in 4.3-25.0% of patients undergoing unilateral radical nephrectomy (table 1) . whether such vari ation is the result of the heterogeneity of the populations studied or differences in pathological evaluation remains unclear. studies utilizing microscopic, thin-step sectioning rather than gross examination or capsular stripping of the removed kidney were more likely to identify multi focal renal lesions. 28, 39 notably, in many instances not only was papillary type 1 rCC multifocal, but clear cell rCC and other histologic types were also found to be multi focal. 17, 19, 22, 28, 30, 33 additionally, preoperative Ct or mri frequently underestimated the presence of multifocality. 22, 38 meanwhile, the importance of multifocality in kidney cancer and its impact on patients and physi cians is largely underappreciated. even the most up-to-date guidelines do not specifically address multifocality as a factor in the management and follow-up of patients. [4] [5] [6] [7] 40 the lack of specific recommendations for follow-up might not only be the result of the relatively small number of patients with bilateral multifocal rCC, but might also result from the fact that a large number of patients with multifocal rCC end up losing at least one renal unit and, therefore, long-term outcomes of patients treated with renal preservation are not available. [10] [11] [12] in one study, 51% of cases scheduled for nephron-sparing surgery (nss) were converted to radical nephrectomy in the setting of multifocal tumors (although many patients treated by radical nephrectomy had rCC tumors greater than 5 cm in size). 12 of concern then, is the possibility that many physicians who treat patients with multi focal rCC might routinely perform nephrectomy, when it might not be indicated in all cases.
after radical nephrectomy, patients with bilateral multi focal renal masses do not seem to be at elevated risk for the development of metastatic disease. series r e V i e W s that compared the outcomes of radical nephrectomy for multi focal versus unifocal rCC found equivalent oncologic outcomes and no additional risk of distant failure associated with the presence of multifocality. 17, 22 while some clinicians might choose to perform radical nephrectomy because of patients' preference or lack of experience in the technical execution of nss for multiple tumors, the most common rationale for total kidney removal is likely to be concern about effective local control and tumor recurrence. in order to address these issues, it is bene ficial to first examine the concept of local recurrence in the setting of multifocal rCC.
Defining local recurrence the evaluation of oncologic outcomes in patients with hereditary or multifocal rCC can be challenging. For patients with multifocal tumors, oncologic success is assessed by metastasis-free survival and the need for subsequent intervention. local recurrence in this population is difficult to assess. unless specific studies, designed to assess clonal origin, are performed on each of the 'locally recurrent' tumors, it is difficult to distinguish between local recurrence resulting from inadequate resection of previous tumors, interval develop ment of new tumors, and detection of tumors that were present at the time of surgery but were too small to appreciate on pre operative and intra operative imaging. if the new tumor is detected in a location remote from the original resection site and clonality studies confirm that the newly detected tumor is not an intrarenal metastasis or a remnant of a previously resected tumor, then one can comfortably conclude that the so-called 'recurrence' is a manifestation of multi focality, rather than a true recurrence. in fact, in patients with bilateral multifocal rCC who undergo nephron-sparing procedures, 'local recurrence' is most likely to be a reflection of the multifocal nature of the disease rather than a failure of surgical therapy. the support for the argument that local recurrences in multifocal disease are a manifestation of multi focality comes from the studies of renal tumors and normal parenchyma resected from patients with hereditary renal cancer syndromes. walther and colleagues 41 estimated that a removed kidney from a patient with von Hippellindau disease can contain as many as 600 solid clear cell carcinoma tumors and 1,100 cysts. a study of kidneys from patients with hereditary papillary renal carcinoma, which is characterized by the development of bilateral multifocal papillary type 1 carcinomas, has predicted that an affected renal unit can contain as many as 3,400 tumors. 42 similarly, patients with Birt-Hogg-Dubé syndrome, which is characterized by development of cutaneous fibrofolliculomas, pulmonary cysts and a variety of renal tumors, are often found to have dozens of lesions in an affected kidney. 43 after appreciating the number of microscopic tumors in patients with bilateral multifocal rCC, one can evaluate oncologic outcomes in more-practical terms, such as metastasis-free survival or subsequent interventionfree survival. overall survival is an appropriate outcome measure as well; however, it needs to be evaluated carefully in light of emerging evidence on the effect of renal function on cardiovascular morbidity and survival.
Management approaches
nephrectomy and renal replacement therapy Considerable progress has been made in the past two decades in the management of bilateral multifocal rCC. earlier management strategies comprised bilateral nephrectomy followed by renal transplantation; these strategies are now less-frequently recommended, having given way to approaches involving aggressive renal preservation. [44] [45] [46] [47] [48] [49] [50] [51] several factors have relegated bilateral nephrectomy to a last resort in the management of patients with bilateral multifocal rCC. First, the risks of dialysis have become more-widely appreciated. [52] [53] [54] second, the american society of transplantation guidelines suggest a 2-year tumor-free interval from rCC before consideration of kidney transplantation, which subjects patients to at least a 2-year period of dialysis. 55 third, the shortage of renal allografts for transplantation can necessitate a prolonged period of dialysis. 54 Fourth, despite advances in renal transplantation, as many as 20-33% of renal allografts will fail by 5 years after transplantation. 56, 57 Fifth, even among patients who receive a transplant, only 75% are alive at 5 years. 57, 58 thus, before bilateral nephrectomy is contemplated, it might be reasonable to identify potential renal donors. in cases of directed renal donation, renal transplantation might become a more viable and reasonable option, which might avoid a prolonged wait for an allograft. in fact, some transplant surgeons perform directed renal transplantation as early as 6 weeks after nephrectomy, with only a short interval of time to be bridged by dialysis.
Despite notable advances, renal replacement therapy remains a significant source of morbidity and mortality. Patients who receive long-term hemodialysis have a cardiovascular mortality rate 10-30 times greater than that of the general population. 56 when considering deaths from myocardial infarction alone, the overall survival of patients on dialysis was considerably worse than that of those without kidney failure, even compared to individuals with comorbid conditions such as dia betes without end-stage renal disease. 59 according to the us renal Data system the mortality rate on dialysis is 22% during the first 2 years, and 15% during the next 3 years. rocco et al. 58 reported that during a 12-month follow-up of patients receiving long-term hemodialysis (excluding inpatients requiring hemodialysis secondary to a medical event), more than 50% of patients required hospitalization, and 20% of all patients died. the mortal ity data obtained from the us renal Data system, however, might not be representative for the population of patients with bilateral multifocal disease, as most patients on dialysis have a long-standing history of other serious comorbidities, while those with multifocal renal masses might be healthier. nevertheless, it is important to recognize the morbidity and risks associated with hemodialysis. additionally, although beyond the scope of this review, the costs of hemodialysis are not insignificant, and approach us$70,000 per person annually.
while the data for dialysis and renal transplantation are derived from patients with other comorbidities such as coronary artery disease, diabetes and hypertension, and might not necessarily reflect the outcomes for the potentially healthier patients with bilateral multifocal recurrent renal lesions, the long-term complications of renal replacement therapy are significant. in many instances, these complications justify an aggressive surgical approach to preserve native renal function.
Maximal renal preservation as the diagnosis and imaging of genitourinary malignancies has evolved, notable progress has been made in the management of patients with kidney cancer. one of the most important advances has been the recognition of the adverse effects of renal insufficiency on longevity and the importance of maximal renal preservation. although randomized prospective studies comparing nss to nephrectomy have not been performed, increasing evidence from retrospective analyses reveals the critical role of preservation of functional renal parenchyma for maintenance of overall health. after analyzing data from over 1,000,000 patients, Go and colleagues 61 found that an incremental decrease in renal function is associated with incremental increases in all-cause hospitalization, cardiovascular morbidity, and all-cause mortality. additionally, several authors have demonstrated a close association between renal insufficiency and cardio vascular disease, while others have suggested that patients treated with radical nephrectomy had shorter overall survival than did those treated with partial nephrectomy. [62] [63] [64] [65] [66] the historic belief that removal of an entire kidney was clinically inconsequential (as most renal donors do well long-term with a solitary renal unit) is no longer supported by data. recent findings demonstrate that patients with rCC are more likely to have underlying renal insuffi ciency than are the healthy donor population. 67 while it is not clear if patients with multifocal tumors are as likely as those with sporadic unifocal rCC to have underlying renal insufficiency, maximal renal preserva tion is still desirable in this setting. in patients with hereditary rCC, for example, multifocal renal tumors present at a younger age than in patients with sporadic renal tumors.
14,15 although they are likely to be healthier at presentation, these patients are still at risk for lifelong comorbidities with potential renal damage. ultimately, however, a potential need exists for renal replacement therapy owing to the likelihood of bi lateral renal involvement and propensity for recurrent or de novo tumor forma tion in these patients. in light of recent knowledge, preservation of renal function in these patients should decrease the future risk of cardiovascular morbidity and mortality.
Treatment of recurrence

Management options
Given the prevalence of multifocality across all patients with rCC, it is not surprising that new kidney tumors are commonly identified in patients treated with prior surgical resection. whether these tumors represent true recurrence from incomplete resection of the initial tumor, or development or detection of a new tumor in the kidney is not always answerable. in practice, this distinction is not important; the management issue remains the same in each case: how to best perform repeat intervention on a previously operated kidney. management options for recurrent tumors include completion nephrectomy, ablation, or repeat partial neph rectomy. the good oncologic efficacy of completion neph rectomy must be balanced against the deleterious effect on renal function. in cases of bilateral involvement or recurrence, performing bilateral nephrectomy exposes patients to the considerable risks of renal replacement therapy. while early and intermediateterm outcomes for ablative therapies in this setting seem to be encouraging in some studies, long-term results are not yet available. additionally, experience with ablative therapy in patients with hereditary kidney cancer or multi focal renal lesions is limited. 68, 69 in certain scenarios ablative technologies can be ineffec tive or inadvisable for patients with multifocal rCC. larger tumors, tumors located in close proximity to renal vessels, collecting system or the uterer, and new lesions on a previously ablated or operated kidney might not be safe to ablate owing to the presence of scarring or adhesions to surrounding viscera. 70 Figure 1 shows a preoperative Ct image from a patient who had prior ablation of two left renal masses. the location of the new lesion was not thought to be safe for ablation owing to its proximity to the spleen and splenic hilum. this patient required open left partial nephrectomy with resection of nine tumors. this case illustrates that in patients with bilateral multifocal recurrent tumors, nss often remains the only alternative to completion nephrectomy and dialysis.
reoperative renal surgery repeat partial nephrectomy can be challenging because of fibrosis, scarring, and obliteration of normal anatomic r e V i e W s planes. the complication rates in our repeat and salvage renal surgeries 71, 72 were greater than that in our previously reported series 73 of de novo partial nephrectomies. in our recent report of repeat surgeries on 51 renal units in 47 patients, the intraoperative complication rate was 35.3%. 72 major postoperative complications occurred in 11.8% of cases and included pulmonary embolism, pancreatic leak, hemodialysis, and one death from perioperative myocardial infarction. these complication rates were higher than those reported for surgically naive patients and repeat surgeries by a mayo Clinic group. [74] [75] [76] [77] [78] these differences can potentially be explained by a higher preva lence of hereditary rCC in our cohort and probably a larger number of tumors resected in our series during the repeat intervention. additionally, our primary surgeries might also have involved resection of larger numbers of tumors, resulting in more-severe scarring, which in turn led to more-difficult repeat procedures. 73 the management of patients with recurrent or de novo renal lesions becomes even more difficult when further intervention is needed after two or more renal surgeries. in a review of the outcomes of salvage partial nephrectomies (defined as three or more surgeries on the same renal unit) the major complication rate was 46%. 71 Half of all major complications were loss of the renal unit, which represented the highest proportion among all reported series, including repeat partial nephrectomies. nonetheless, three-quarters of the operated kidneys in this series were preserved. although the median duration of follow-up in this cohort was only 25 months, some of the patients remained free from metastatic disease and dialysis for as long as 7 years after surgery. Despite a high complication rate, the rationale for salvage nss is supported by the high survival rate (100%) of this cohort.
additional challenges with reoperative renal surgery are seen in patients who have undergone failed renal ablation, in patients in whom new tumors are in locations not amendable to ablation, in patients with postablation scarring, and in those who have developed adhesions to adjacent organs. in these patients, surgical resection might be the only viable option. in a study from the Cleveland Clinic, partial nephrectomy was successfully performed in only 2 of 10 patients who underwent attempted extirpa tion of disease recurrence after ablative therapy; the remaining patients underwent radical nephrectomy or had the procedure aborted. one successful nss was done after radiofrequency ablation and one was completed after cryoablation. 79 at our institution we were able to complete all of 16 attempted partial nephrectomies after previous radiofrequency ablation without loss of a renal unit. 70 these surgeries, however, were complicated by higher rates of urine leakage and reoperation when compared to primary or repeat partial nephrectomy. 12 of 16 (75%) cases involved very difficult dissection around the previously ablated tumor and 5 cases (31%) were complicated by intraoperative pleural injury. table 2 describes perioperative outcomes of primary, repeat, salvage, and postradiofrequency ablation partial nephrectomies performed at our institution for renal masses in patients with multifocal renal tumors. [70] [71] [72] [73] similar to any oncologic intervention, the outcomes of repeat renal surgery should be assessed by not only perioperative, but also functional and oncologic outcomes. table 3 shows an increased rate of loss of renal units (atrophy of the renal remnant or nephrectomy) with each 
All the procedures listed in this table were performed at the National Cancer Institute. While all patients had a history of multifocal disease, some surgeries were performed for unifocal tumors. Abbreviations: CV, cardiovascular; EBL, estimated blood loss; NA, not available; Nx, nephrectomy; RFA, radiofrequency ablation. f o C u s o n k i d n e y C A n C e r subsequent intervention. those patients with a remaining kidney had only a modest elevation of serum creatinine and decrease in creatinine clearance rate at least 3 months after surgery. the oncologic rationale for continued aggressive surgical intervention is provided by our own cohort, which shows excellent metastasis-free and overall survival, in excess of 90%, at intermediate-term follow-up (table 4) . [71] [72] [73] 80 our approach in addition to ensuring effective oncologic control and maximal renal preservation, the management of patients with bilateral recurrent multifocal renal masses is focused on minimizing the number of interventions and perioperative morbidity. over the course of a number of years of treating patients with bilateral multifocal disease at our institution, several nuances of management have been developed (Figure 2 ). this suggested approach is being developed and used by the urologic oncology service, based on our experience in managing patients with bilateral multifocal disease.
First, we utilize percutaneous biopsy to guide the management of patients who present with bilateral renal masses. while discussion of the accuracy, advantages and disadvantages of percutaneous renal biopsy is beyond the scope of this review, we find that a pathology-specific approach in patients with unknown diagnosis can best direct further work-up, genetic testing, necessity of intervention, and type of resection. if the patient presents with bilateral renal masses and a known hereditary syndrome, the percutaneous biopsy can be avoided, as specific hereditary syndromes are associated with certain types of tumors. in most cases, percutaneous biopsy allows the urologic surgeon to look carefully for associated syndromes and plan the type of resection (enucleation versus resection with wider margins).
with the exception of tumors suspicious for papillary type 2 rCC and those associated with hereditary leio myomata rCC, most patients with familial forms of bi lateral clear cell rCC, papillary type 1 rCC, chromo phobe rCC, or hybrid oncocytic neoplasms are observed until the largest mass reaches 3 cm in 51, 81, 82 it has been applied to management of familial papillary type 1 rCC, chromophobe rCC, and hybrid oncocytic neoplasms, without evidence of metastatic disease to date. [71] [72] [73] 81 this strategy allows an increased interval between proce dures, thus preserving native renal function and avoiding morbidity caused by premature intervention. By contrast, tumors suspicious for papillary type 2 rCC are not observed and patients are advised to undergo early surgical resection. Finally, many patients with bilateral multifocal clear cell rCC and bilateral multifocal papillary type 1 rCC without evidence of a known hereditary cancer syndrome or detectable germline mutation are also managed with the aforementioned 3 cm rule. this management strategy is utilized after partial nephrectomy on at least one side if the final pathologic examination does not reveal aggressive histologic pattern, indicative of papillary type 2 rCC or high-grade disease.
in addition, we have developed certain techniques to decrease the intraoperative morbidity of subsequent surgeries. we attempt to perform surgery via a retroperitoneal approach, to minimize future adhesions of abdominal viscera to the raw surface of the kidney. another advantage of this approach is the preservation of a small, confined retroperitoneal space in case of postoperative bleeding. we also attempt to minimize intraoperative dissection of the hilum, and if clamping is needed, we frequently clamp artery and vein en bloc to preserve the adventitial layers encasing the main renal vessels. we routinely use intraoperative ultrasonography and find that it facilitates identification of wholly intraparenchymal lesions and allows maximal debulking of the operated kidney. 83, 84 we believe that a morethorough resection allows a longer interval between subsequent interventions.
as we perform aggressive resections that frequently require resection of dozens of lesions from the same renal unit, we attempt to minimize the potential ischemia time by performing the tumor resections off clamp, starting with easier and more-superficial tumors, and proceeding to more-endophytic and hilar lesions. additionally, as kidneys with multifocal lesions have a propensity for tumor development and have a 'true field defect' (multiple areas of the renal parenchyma affected), we choose to perform most surgeries by enuclear resection, with precise repair of the bleeding vessels or hemostasis using thrombin-soaked gel foam, and minimal resection of unaffected renal parenchyma. Frozen section analysis is rarely needed as most surgical planning is done preoperatively. Finally, at the end of surgery, the Gerota fascia is approximated over the kidney, if possible. this maneuver facilitates easier dissection during subsequent operations and might help with hemostasis.
Conclusions
with an estimated 5% prevalence of bilateral mutlifocal rCC, a large number of patients will face the complex medical and surgical decisions associated with this disease. these patients are at increased risk of developing locally recurrent disease and require repeat interventions to preserve their native renal function. renal surgery for multifocal bilateral recurrent renal masses is technically demanding and associated with high rates of intraoperative and postoperative complications. although these surgeries are associated with high blood loss and perioperative morbidity, most renal units can be saved during repeated interventions. Before embarking on repeat renal surgery a patient needs to be appropriately counseled regarding the risks and benefits of reoperative renal surgery. at present, faced with limited alternatives for this patient population, our data argue that, despite higher operative morbidity, repeat nephron-sparing interventions are a better alternative than nephrectomy and renal replacement therapy.
Review criteria
We searched PubMed for articles published in English in the past 30 years using the following terms: "multifocal renal cell carcinoma", "bilateral renal cell carcinoma", "recurrent renal cell carcinoma", "ablation of renal masses", "management of RCC recurrences", and "hereditary renal cell carcinoma". The full-text articles were assessed and reviewed for pertinent information, and the reference lists were searched to identify additional sources of information. When relevant, abstracts and database references were also included in this Review.
